Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.

ABSTRACT:

Background

New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known.

Objective

To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx.

Design

NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials.gov: NCT04321616).

Setting

23 hospitals in Norway.

Patients

Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infe

SUBMITTER: Barratt-Due A 

PROVIDER: S-EPMC8279143 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature